Hallucinogen Use Disorders.
Hardaway R, Schweitzer J, Suzuki J.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):489-96. doi: 10.1016/j.chc.2016.03.006. Epub 2016 Apr 18.
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Hallucinogens.
Nichols DE.
Pharmacol Ther. 2004 Feb;101(2):131-81. doi: 10.1016/j.pharmthera.2003.11.002.
Psilocybin--summary of knowledge and new perspectives.
Tylš F, Páleníček T, Horáček J.
Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. doi: 10.1016/j.euroneuro.2013.12.006. Epub 2013 Dec 17.
Psychedelic-inspired approaches for treating neurodegenerative disorders.
Saeger HN, Olson DE.
J Neurochem. 2022 Jul;162(1):109-127. doi: 10.1111/jnc.15544. Epub 2021 Dec 5.
Harm potential of magic mushroom use: a review.
van Amsterdam J, Opperhuizen A, van den Brink W.
Regul Toxicol Pharmacol. 2011 Apr;59(3):423-9. doi: 10.1016/j.yrtph.2011.01.006. Epub 2011 Jan 21.
Psychedelics: Threshold of a Therapeutic Revolution.
Heal DJ, Smith SL, Belouin SJ, Henningfield JE.
Neuropharmacology. 2023 Sep 15;236:109610. doi: 10.1016/j.neuropharm.2023.109610. Epub 2023 May 27.
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J, Hallak J, Dursun SM, Baker G.
Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR, Richards WA, McCann U, Jesse R.
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. doi: 10.1007/s00213-006-0457-5. Epub 2006 Jul 7.
